When Will Amicus Therapeutics, Inc. (NASDAQ:FOLD) Become Profitable? [Yahoo! Finance]
Why Is Amicus Therapeutics (FOLD) Down 8.1% Since Last Earnings Report? [Yahoo! Finance]
Amicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) Report [Yahoo! Finance]
Amicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) Report
Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its price target lowered by analysts at JPMorgan Chase & Co. from $21.00 to $19.00. They now have an "overweight" rating on the stock.